Uncategorized

Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3

Published

6 days ago

on

Revolution Medicines reported Monday that its experimental KRAS inhibitor called daraxonrasib succeeded in a registrational trial for pancreatic cancer.

And now, the company plans to ask the FDA to approve the therapy under the agency’s …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version